Skip to main content
Premium Trial:

Request an Annual Quote

Spotfire Plans 2001 Initial Public Offering

NEW YORK, Sept 19 – Spotfire, a developer of analytics software used by pharmaceutical and biotechnology companies, is considering an initial public offering on the Nasdaq next year.

Chris Ahlberg, Spotfire’s CEO, said the Cambridge, Mass.-based company expects to use money from an IPO for general business purposes. He declined to say how much the company hopes to raise.

The IPO would cap a string of offerings by other bioinformatics players. Compugen (Nasdaq: CGEN) of Tel Aviv, Lion Bioscience (Neuer Markt: LIO; Nasdaq: LEON) of Heidelberg, and Rosetta Inpharmatics (Nasdaq: RSTA) all went public this summer. And NetGenics, InforMax, and Genomica are all in the pipeline.

Ahlberg said that Spotfire’s software has broad applications, which should help to expand the company’s revenue bases. Besides biotechnology customers, Spotfire has users in the chemicals, semiconductor, and manufacturing industries.  

The company’s products use a single workspace to combine data, analytical tools, and reporting capabilities needed for decision-making by individuals and groups.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.